IDYA Stock Risk & Deep Value Analysis
IDEAYA Biosciences Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About IDYA Stock
We analyzed IDEAYA Biosciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IDYA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
IDYA Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is clinical failure of the OptimUM-02 trial. Negative data could lead to a significant re-evaluation of darovasertib's potential and substantial stock price decline, jeopardizing the company's lead program and potentially necessitating further dilutive financing.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Lack of detailed current financial metrics (cash position, burn rate) in provided data brief, common for early-stage biotechs.
- ⚠
High inherent risk associated with binary clinical trial outcomes, especially for a company with limited commercial revenue.
- ⚠
Dependence on successful clinical development and regulatory approvals for future revenue generation.
Upcoming Risk Events
- 📅
Negative or inconclusive results from the OptimUM-02 trial (April 13, 2026).
- 📅
Clinical trial failures for other pipeline assets (IDE161, IDE849, IDE574).
- 📅
Delay in regulatory approval processes or unfavorable regulatory decisions.
When to Reconsider
- 🚪
OptimUM-02 trial results announced as statistically insignificant or negative for primary endpoint.
- 🚪
Significant delays in ongoing or planned clinical trials for key pipeline assets.
- 🚪
Announcements of substantial share dilution without clear justification or new funding.
Unlock IDYA Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does IDEAYA Biosciences Inc (IDYA) Do?
Market Cap
$2.90B
Sector
Healthcare
Industry
Biotechnology
Employees
131
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Visit IDEAYA Biosciences Inc WebsiteInvestment Thesis
IDEAYA is a high-risk, high-reward investment positioned at the forefront of synthetic lethality oncology. Its lead asset, darovasertib, is on the cusp of pivotal Phase 2/3 data that could unlock substantial value, supported by a validated platform, strong partnerships with GSK and AstraZeneca, and a robust pipeline. Success in its clinical programs could lead to significant market share in underserved cancer indications, justifying its 10x growth potential.
Is IDYA Stock Undervalued?
Unlock the full AI analysis for IDYA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
IDYA Price Targets & Strategy
12-Month Target
$95.00
Bull Case
$150.00
Bear Case
$15.00
Valuation Basis
Based on successful OptimUM-02 de-risking leading to market re-rating towards 4x estimated peak sales potential of $2B across its diversified synthetic lethality pipeline.
Entry Strategy
Consider accumulation below $35 prior to the OptimUM-02 readout, or on any post-catalyst pullback if results are positive, targeting support levels.
Exit Strategy
Take initial profits at $70-$80; Re-evaluate full position at $100+. Implement a stop-loss order if clinical data disappoints, or if stock drops below $20 post-catalyst.
Portfolio Allocation
8-12% for aggressive risk tolerance; 3-6% for moderate risk tolerance due to binary event risk.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is IDYA Financially Healthy?
Valuation
P/E Ratio
-6.40
Forward P/E
-7.60
PEG Ratio
0.08
Price/Book
1.90
Price/Sales
13.40
Balance Sheet
Cash & Equivalents
$1.20B
Does IDYA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is durable due to the difficulty and cost of drug development, strong IP protection for novel targets in synthetic lethality, and the deep expertise required. Strategic partnerships further reinforce its position by leveraging larger infrastructure.
Moat Erosion Risks
- •Failure of clinical trials leading to loss of lead assets and platform validation.
- •Expiration or challenge of key patents allowing generic or biosimilar competition.
- •Emergence of superior competing therapies from other oncology developers.
IDYA Competitive Moat Analysis
Sign up to see competitive advantages
IDYA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - No specific data available, but an imminent catalyst suggests elevated retail attention.
Institutional Sentiment
Positive - Demonstrated by strategic collaborations with major pharmaceutical companies like GSK and AstraZeneca, validating platform and pipeline.
Insider Activity (Form 4)
No specific buy/sell transactions from insiders reported in the last 90 days. The search results reference Joshua Bleharski, Ph.D., Chief Financial Officer, as an investor contact. One filing notes The Vanguard Group underwent internal realignment on January 12, 2026, and now reports holdings on a disaggregated basis through subsidiaries.
Options Flow
Normal options activity - No specific unusual options flow data was provided in the brief.
Earnings Intelligence
Next Earnings
Next earnings date is not provided, but the next material catalyst is OptimUM-02 topline results on April 13, 2026.
Surprise Probability
High (for clinical trial results, as outcomes are binary and can lead to significant market reactions).
Historical Earnings Pattern
For clinical-stage biotechs, stock price reaction to pivotal trial results is typically highly volatile and binary, with significant moves up or down depending on the outcome.
Key Metrics to Watch
Competitive Position
Top Competitor
Gilead Sciences (GILD)
Market Share Trend
Not applicable as the company is pre-revenue. It aims to create new market share within targeted oncology segments (e.g., uveal melanoma) by introducing novel therapies.
Valuation vs Peers
As a clinical-stage biotech, IDEAYA trades at a significant premium on traditional valuation metrics (e.g., P/E) compared to commercialized peers like Gilead, reflecting its potential for future growth rather than current profitability. It's valued based on pipeline potential and de-risking events.
Competitive Advantages
- •Proprietary synthetic lethality platform and extensive intellectual property.
- •Strategic partnerships with leading pharmaceutical companies (GSK, AstraZeneca) providing validation and funding.
- •Diversified pipeline targeting multiple difficult-to-treat cancers.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive IDYA Stock Higher?
Near-Term (0-6 months)
- •Topline results from Phase 2/3 OptimUM-02 trial (Darovasertib) on April 13, 2026
- •Multiple Phase 1 trial initiations (IDE574, IDE849/IDE161 combinations) from March-April 2026, leading to initial data readouts in late 2026/early 2027.
- •Investor Relations events: Bank of America Merrill Lynch Health Care Conference (May 12, 2026), Stifel forum (May 19, 2026).
Medium-Term (6-18 months)
- •Potential NDA/BLA filing and accelerated approval for darovasertib in uveal melanoma post-OptimUM-02 success (2027-2028).
- •Progression of IDE161 (HRD tumors) into later-stage trials.
- •Further expansion of collaborations with GSK, AstraZeneca, or new pharma partners.
Long-Term (18+ months)
- •Establishment of IDEAYA as a leader in synthetic lethality oncology, capturing significant market share across multiple indications.
- •Pipeline maturation with multiple approved therapies contributing to revenue.
- •Disruption of traditional oncology treatment paradigms with highly targeted therapies.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for IDYA?
- ✓
Positive efficacy and safety data from the OptimUM-02 trial.
- ✓
Updates on regulatory interactions and potential for accelerated approval.
- ✓
New partnership announcements or expansion of existing collaborations.
Bull Case Analysis
See what could go right with Premium
Competing with IDYA
See how IDEAYA Biosciences Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
IDEAYA Biosciences Inc IDYA | $2.9B | 8.8 | -6.4 | — | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How IDEAYA Biosciences Inc Makes Money
IDEAYA Biosciences is a biotechnology company focused on the discovery and development of precision medicines for cancer, primarily using synthetic lethality. This innovative approach targets cancer cells by exploiting specific genetic vulnerabilities, leaving healthy cells unharmed. The company generates revenue through strategic collaborations with larger pharmaceutical companies, which provide upfront payments, research funding, and potential milestone payments and royalties on future sales. Eventually, if its drugs are approved, it would generate revenue from product sales, either independently or through its partners, aiming to address significant unmet medical needs in oncology.
Read Full Business Model BreakdownFAQ
What is the DVR Score for IDEAYA Biosciences Inc (IDYA)?
As of April 11, 2026, IDEAYA Biosciences Inc has a DVR Score of 8.8 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of IDEAYA Biosciences Inc?
IDEAYA Biosciences Inc's market capitalization is approximately $2.9B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does IDEAYA Biosciences Inc use?
IDYA is the ticker symbol for IDEAYA Biosciences Inc. The company trades on the NMS.
What is the risk level for IDYA stock?
Our analysis rates IDEAYA Biosciences Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of IDYA?
IDEAYA Biosciences Inc currently has a price-to-earnings (P/E) ratio of -6.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is IDEAYA Biosciences Inc's revenue growing?
IDEAYA Biosciences Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is IDYA stock profitable?
IDEAYA Biosciences Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the IDYA DVR analysis updated?
Our AI-powered analysis of IDEAYA Biosciences Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 11, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IDYA (IDEAYA Biosciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.